Some aspects of comorbidity between psoriasis and bronchopulmonary pathology (literature review)
https://doi.org/10.36604/1998-5029-2025-98-163-174
Abstract
Introduction. Psoriasis is one of the most common dermatoses among both adults and children. Its course associated with pulmonary diseases in adult patients has been described.
Aim. To analyze the accumulated data on the prevalence and possible pathophysiological mechanisms of inflammation in psoriasis and chronic bronchopulmonary diseases driven by shared processes and genetic predisposition, in order to assess the potential for future prognostic approaches and early prevention strategies.
Materials and methods. A literature search spanning more than 50 years was conducted in the PubMed, PlamX, ResearchGate, The BMJ, and Elsevier databases, selecting articles categorized as "Clinical Trial", "Meta-Analysis", "Review", and "Systematic Review".
Results. Analysis of published studies revealed a relatively low percentage of comorbidity between psoriasis and bronchopulmonary pathology. Several common pathogenetic mechanisms of inflammation and the effects of specialized therapies are presented. Shared risk factors contributing to the development of psoriasis and other diseases—particularly those affecting the bronchopulmonary system—have been identified. These similarities include immune processes, cytokine profiles, and types of immune cells involved. Several genetic variants linking psoriasis with impaired lung function have been analyzed, laying the groundwork for future research.
Conclusion. The insufficient study of the co-occurrence of these two nosological entities – especially in childhood necessitates further investigation and identification of – biomarkers at earlier stages of ontogenesis to enable timely diagnosis, prognosis, and evidence-based therapeutic interventions.
About the Authors
S. V. Suprun
Khabarovsk Branch of the Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Maternity and Childhood Protection
Russian Federation
Russian Federation
Stefania V. Suprun, MD, PhD, DSc (Med.), Main Staff Scientist of the Group of Health and Environmental Problems of Mother and Child Health, Laboratory of Integral Methods of Bronchopulmonary and Perinatal Pathology Research
49/1 Voronezhskaya Str., Khabarovsk, 680022
M. I. Makeeva
Khabarovsk Branch of the Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Maternity and Childhood Protection; Regional State Budgetary Healthcare Institution "Regional Dermatovenerologic Dispensary" of the Ministry of
Healthcare of the Khabarovsk Krai
Russian Federation
Russian Federation
Mariya I. Makeeva, Head of the Dermatovenereology Department, Dermatovenereologist
49/1 Voronezhskaya Str., Khabarovsk, 680022
5 Angarskaya Str., Khabarovsk, 680003
References
1. [Clinical recommendations. Psoriasis]. Moscow: Obshcherossiyskaya obshchestvennaya organizatsiya "Rossiyskoye obshchestvo dermatovenerologov i kosmetologov"; 2023 (in Russian). Available at: https://cr.minzdrav.gov.ru/previewcr/234_2
2. Skayem C., Taieb C., Halioua B., Baissac C., Saint Aroman M. Epidemiology of psoriasis: a worldwide global study. Acta Derm. Venereol. 2025; 105:adv42945. https://doi.org/10.2340/actadv.v105.42945
3. Grishko T.N., Oparin R.B., Basse F.B., Trufanova E.Yu., Mordovtsev V.N. [Psoriasis in children]. Vestnik Dermatologii i Venerologii 2005; 1:59 (in Russian).
4. Murzina E. Pediatric psoriasis: clinical features and course. OAJBS 2020; 1(5):207–209. https://doi.org/10.38125/OAJBS.000147
5. Agafonova Yu.V., Simonova D.L., Simonov S.N. [Quality of life assessment among children with psoriasis]. Meditsina i fizicheskaya kul'tura: nauka i praktika = Medicine and physical education: science and practice 2021; 3(4):41– 48 (in Russian). https://doi.org/10.20310/2658-7688-2021-3-4(12)-41-48
6. Augustin M., Glaeske G., Radtke M.A., Christophers E., Reich K., Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br. J. Dermatol. 2010; 162(3):633–636. https://doi.org/10.1111/j.1365-2133.2009.09593.x
7. Daudén E., Castañeda S., Suárez C., García-Campayo J., Blasco A.J., Aguilar M.D., Ferrándiz C., Puig L., Sánchez-Carazo J.L. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2013; 27(11):1387–1404. https://doi.org/10.1111/jdv.12024
8. Salihbegovic E.M., Hadzigrahic N., Suljagic E., Kurtalic N., Hadzic J., Zejcirovic A., Bijedic M., Handanagic A. Psoriasis and dyslipidemia. Mater. Sociomed. 2015; 27(1):15–17. https://doi.org/10.5455/msm.2014.27.15-17
9. Osigwe P.C., Agomoh C.E., Osigwe I.S. The association between psoriasis and atherosclerotic cardiovascular disease: a systematic review and meta-analysis of observational studies. Cureus 2024; 16(6):e63379. https://doi.org/10.7759/cureus.63379
10. Coto-Segura P., Eiris-Salvado N., González-Lara L., Queiro-Silva R., Martinez-Camblor P., Maldonado-Seral C., García-García B., Palacios-García L., Gomez-Bernal S., Santos-Juanes J. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: A systematic review and meta-analysis. Br. J. Dermatol. 2013; 169(4):783–793. https://doi.org/10.1111/bjd.12473
11. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies. Nutr. Diabetes 2012; 2(12):e54. https://doi.org/10.1038/nutd.2012.26
12. Fu Y., Lee C.-H., Chi C.-C. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018; 154(12):1417–1423. https://doi.org/10.1001/jamadermatol.2018.3631
13. Jing X., Zhuyuan W., Aijun C., Jianxia X., Kun H, Ping W. Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Front. Med. 2023; 10:1175477. https://doi.org/10.3389/fmed.2023.1175477
14. Rachakonda T.D., Schupp C.W., Armstrong A.W. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 2014; 70( 3):512–516. https://doi.org/10.1016/j.jaad.2013.11.013
15. Tanimura K., Nouraie S.M., Chandra D., Nyunoya T. Pulmonary comorbidities in psoriasis are associated with a high risk of respiratory failure. J. Int. Med. Res. 2023; 51(6):3000605231182881 https://doi.org/10.1177/03000605231182881
16. Ishikawa G., Dua S., Mathur A., Acquah S.O., Salvatore M., Beasley M.B., Padilla M.L. Concomitant interstitial lung disease with psoriasis. Can. Respir. J. 2019; 2019:5919304. https://doi.org/10.1155/2019/5919304
17. Kozlov V.K., Lebedko O.A., Morozova N.V., Pichugina S.V., Yakovlev E.I., Gandurov S.G., Evseeva G.P., Suprun S.V., Nagovitsyna E.B., Kuderova N.I. [Chronic bronchopulmonary diseases in children occurring with bronchial obstruction syndrome]. Bûlleten' fiziologii i patologii dyhaniâ = Bulletin Physiology and Pathology of Respiration 2021; 82:62– 73 (in Russian). https://doi.org/10.36604/1998-5029-2021-82-62-73
18. Fayrushina I.F., Kirillova E.R., Mukhametshina E.I., Abdulganieva D.I. [Diversity of comorbid pathology in patients with psoriatic arthritis of young and middle age]. Vestnik sovremennoy klinicheskoy meditsiny = The Bulletin of Contemporary Clinical Medicine 2021; 14(1):47–52 (in Russian). https://doi.org/10.20969/VSKM.2021.14 (1).47-52
19. Kubanov A.A., Bogdanova E.V. [Epidemiology of psoriasis in the Russian Federation (according to the registry data)]. Vestnik Dermatologii i Venerologii 2022; 98(2):33–41 (in Russian). https://doi.org/10.25208/vdv1268
20. Mleczko M., Gerkowicz A., Krasowska D. Chronic inflammation as the underlying mechanism of the development of lung diseases in psoriasis: a systematic review. Int. J. Mol. Sci. 2022; 23(3):1767. https://doi.org/10.3390/ijms23031767
21. Adaskevich V.P., Katina М.А. [Clinical peculiarities of psoriasis in children and adolescents]. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum 2018; 2:83–88 (in Russian). https://doi.org/10.26442/2413-8460_2018.2.83-88
22. Galili E., Barzilai A., Twig G., Caspi T., Daniely D., Shreberk-Hassidim R., Astman N. Allergic rhinitis and asthma among adolescents with psoriasis: a population-based cross-sectional study. Acta Derm. Venereol. 2020; 100(10):adv00133. https://doi.org/10.2340/00015555-3485
23. Ziyab A.H., Ali Y., Zein D., Al-Kandari M., Holloway J.W., Karmaus W. Association of psoriasis with allergic multimorbidity of asthma, rhinitis, and eczema among adolescents: a cross-sectional study. Allergy Asthma Clin. Immunol. 2024; 20(1):41. https://doi.org/10.1186/s13223-024-00907-6
24. [Clinical guidelines. Chronic bronchitis]. Moscow: Rossiyskoye respiratornoye obshchestvo; 2024 (in Russian). Available at: https://cr.minzdrav.gov.ru/preview-cr/655_2
25. Konovalov K.M., Baranov A.A., Lapkina N.A., Abaitova N.E., Borisova O.L. [Clinical indices and laboratory markers for evaluating the immune-mediated inflammation in rheumatoid arthritis: the impact of COVID-19]. Pacientoorientirovannaya medicina i farmaciya = Patient-oriented medicine and pharmacy 2025; 3(1):49–58 (in Russian). https://doi.org/10.37489/2949-1924-0081
26. Mateu-Arrom L., Puig L. Genetic and epigenetic mechanisms of psoriasis. Genes (Basel) 2023; 14:1619. https://doi.org/10.3390/ genes14081619
27. Makhmudova M.A. [Epigenetic mechanisms in the pathogenesis of autoimmune diseases]. Ekonomika i sotsium 2025; 3(130-2):618–620 (in Russian).
28. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J. Eur. Acad. Dermatol. Venereol. 2012; 26(Suppl.2):3–11. https://doi.org/10.1111/j.1468-3083.2011.04410.x
29. Akbarzadeh R., Humrich J.Y., Nemeth T., Amber K.T. Editorial: Innate immune dysregulation: a driving force of autoimmunity and chronic inflammation. Front. Immunol. 2025; 16:1632416. https://doi.org/10.3389/fimmu.2025.1632416
30. Sanchez A.P.G. Better understanding the immunopathogenesis of psoriasis. Clin. Res. Dermatol. Open Access 2017; 4(1):1–2. http://dx.doi.org/10.15226/2378-1726/4/1/00151
31. Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J. Allergy Clin. Immunol. 2017; 140(3):645–653.https://doi.org/10.1016/j.jaci.2017.06.010
32. Hawkes J.E., Yan B.Y., Chan T.C., Krueger J.G. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J. Immunol. 2018; 201(6):1605–1613. https://doi.org/10.4049/jimmunol.1800013
33. Grän F., Kerstan A., Serfling E., Goebeler M., Muhammad K. Current developments in the immunology of psoriasis. Yale J. Biol. Med. 2020; 93(1):97–110.
34. von Stebut E., Boehncke W.H., Ghoreschi K., Gori T., Kaya Z., Thaci D. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front. Immunol. 2019; 10:1–15. https://doi.org/10.3389/fimmu.2019.01686
35. Krueger J.G., Brunner P.M. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation, and associated comorbidities. Exp. Dermatol. 2017; 27(1):115–123. https://doi.org/10.1111/exd.13467
36. Matozzi C., Salvi M., D’Epiro S., Giancristoforo S., Macaluso L., Luci C. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature. Dermatology 2013; 227(2):134–145. https://doi.org/10.1159/000353398
37. Blauvelt A., Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol. 2018; 55(3):379–390. https://doi.org/10.1007/s12016-018-8702-3
38. Lin A.M., Rubin C.J., Khandpur R., Wang J.Y., Riblett M., Yalavarthi S., Villanueva E.C. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 2011; 187(1):490–500. https://doi.org/10.4049/jimmunol.1100123
39. Benezeder T., Wolf P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin. Immunopathol. 2019; 41(6):633–644. https://doi.org/10.1007/s00281-019-00766-z
40. Diani M., Altomare G., Reali E. T helper cell subsets in clinical manifestations of psoriasis. J. Immunol. Res. 2016; 2016:7692024. https://doi.org/10.1155/2016/7692024
41. Ray A., Kolls J.K. Neutrophilic inflammation in asthma and association with disease severity. Trends Immunol. 2017; 38(12): 942–954. https://doi.org/10.1016/j.it.2017.07.003
42. Urbanowicz R.A., Lamb J.R., Todd I., Corne J.M., Fairclough L.C. Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respir. Res. 2010; 11:76. https://doi.org/10.1186/1465-9921-11-76
43. Di Stefano A., Caramori G., Gnemmi I., Contoli M., Vicari C., Capelli A., Magno F., D’Anna S.E., Zanini A., Brun P. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin. Exp. Immunol. 2009; 157(2):316–324. https://doi.org/10.1111/j.1365-2249.2009.03965.x
44. Facco M., Cabrelle A., Teramo A., Olivieri V., Gnoato M., Teolato S., Ave E., Gattazzo C., Fadini G.P., Calabrese F. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66(2):144–150. https://doi.org/10.1136/thx.2010.140319
45. Molet S., Hamid Q., Davoine F., Nutku E., Taha R., Pagé N., Olivenstein R., Elias J., Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 2001; 108(3):430–438. https://doi.org/10.1067/mai.2001.117929
46. Hellermann G.R., Nagy S.B., Kong X., Lockey R.F., Mohapatra S.S. Mechanism of cigarette smoke condensateinduced acute inflammatory response in human bronchial epithelial cells. Respir. Res. 2002; 3:22. https://doi.org/10.1186/rr166
47. Ma W.-J., Sun Y.-H., Jiang J.-X., Dong X.-W., Zhou J.-Y., Xie Q.-M. Epoxyeicosatrienoic acids attenuate cigarette smoke extract-induced interleukin-8 production in bronchial epithelial cells. Prostaglandins Leukot. Essent. Fat. Acids 2015; 94:13–19. https://doi.org/10.1016/j.plefa.2014.11.005
48. Keatings V.M., Collins P.D., Scott D.M., Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996; 153(1):530–534. https://doi.org/10.1164/ajrccm.153.2.8564092
49. Elder J.T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009; 10(3): 201–209. https://doi.org/10.1038/gene.2009.11
50. Weidinger S., Willis-Owen S.A.G., Kamatani Y., Baurecht H., Morar N., Liang L., Edser P., Street T., Rodriguez E., O’Regan G.M. A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. Hum. Mol. Genet. 2013; 22(23): 4841–4856. https://doi.org/10.1093/hmg/ddt317
51. Kere J. Mapping and identifying genes for asthma and psoriasis. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2005; 360(1460):1551–1561. https://doi.org/10.1098/rstb.2005.1684
52. Tanimura K., Aldrich M.C., Jaworski J., Xing J., Okawa S., Chandra D., Nouraie S.M., Nyunoya T. Identifying a genetic link between lung function and psoriasis. Ann. Hum. Genet. 2025; 89(2-3):89–95. https://doi.org/10.1111/ahg.12587
53. Östling J., van Geest M., Schofield J.P.R., Jevnikar Z., Wilson S., Ward J., Lutter R., Shaw D.E., Bakke P.S., Caruso M. IL-17-high asthma with features of a psoriasis immunophenotype. J. Allergy Clin. Immunol. 2019; 144(5): 1198–1213. https://doi.org/10.1016/j.jaci.2019.03.027
54. Hollox E.J., Huffmeier U., Zeeuwen P.L.J.M., Palla R., Lascorz J., Rodijk-Olthuis D., van de Kerkhof P.C.M., Traupe H., de Jongh G., den Heijer M. Psoriasis is associated with increased beta-defensin genomic copy number. Nat. Genet. 2008; 40(1):23–25. https://doi.org/10.1038/ng.2007.48
55. Janssens W., Nuytten H., Dupont L.J., Van Eldere J., Vermeire S., Lambrechts D., Nackaerts K., Decramer M., Cassiman J.-J., Cuppens H. Genomic copy number determines functional expression of β-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 182(2):163–169. https://doi.org/10.1164/rccm.200905-0767OC
56. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., Gudjonsson J.E., Li Y., Tejasvi T., Feng B.-J. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 2009; 41(2):199–204. https://doi.org/10.1038/ng.311
57. Kim H.S., Choi D., Lim L.L., Allada G., Smith J.R., Austin C.R., Doyle T.M., Goodwin K.A., Rosenbaum J.T., Martin T.M. Association of interleukin 23 receptor gene with sarcoidosis. Dis. Markers 2011; 31(1):17–24. https://doi.org/10.1155/2011/185106
58. Lateef O., Shakoor N., Balk R.A. Methotrexate pulmonary toxicity. Expert Opin. Drug Saf. 2005; 4(4):723–730. https://doi.org/10.1517/14740338.4.4.723
59. Hünür M., Öğüt T.S., Çelik E., Erbasan F., Dilbil M., Nokay M. Lung involvement in patients with psoriatic arthritis. Arch. Rheumatol. 2024; 39(4):631–640. https://doi.org/10.46497/ArchRheumatol.2024.10537
60. Nadarajan P., Fabre A., Kelly E. Sulfasalazine: a rare cause of acute eosinophilic pneumonia. Respir. Med. Case Rep. 2016; 18:35–36. https://doi.org/10.1016/j.rmcr.2016.03.006
61. Kamata M., Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int. J. Mol. Sci. 2020; 21(5):1690. https://doi.org/10.3390/ijms21051690
62. Yiu Z.Z.N., Smith C.H., Ashcroft D.M., Lunt M., Walton S., Murphy R., Reynolds N.J., Ormerod A.D., Griffiths C.E.M., Warren R.B. Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J. Investig. Dermatol. 2018; 138(3):534–541. https://doi.org/10.1016/j.jid.2017.10.005
63. Goujdami N., Haij K., Ezzine J., Lairani F., Nacir O., Ait Errami A., Oubaha S., Samlani Z., Krati K. Asthma development under adalimumab therapy: a clinical case analysis. SAS J. Med. 2024; 10(10):1043–1045. https://doi.org/10.36347/sasjm.2024.v10i10.008
64. Eren Dagli C., Akgedik R., Yildirim B.B., Gunaydin R. Adalimumab and etanercept induced asthma. Eur. Respir. J. 2015; 46:650. https://doi.org/10.1183/13993003.congress-2015.PA650
65. Herrinton L.J., Harrold L.R., Liu L., Raebel M.A., Taharka A., Winthrop K.L., Solomon D.H., Curtis J.R., Lewis J.D., Saag K.G. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol. Drug Saf. 2013; 22(4):394–402. https://doi.org/10.1002/pds.3409
66. Campa M., Mansouri B., Warren R., Menter A. A review of biologic therapies targeting il-23 and il-17 for use in moderate-to-severe plaque psoriasis. Dermatol. Ther. 2016; 6(1):1–12. https://doi.org/10.1007/s13555-015-0092-3
67. Durham A.L., Caramori G., Chung K.F., Adcock I.M. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl. Res. 2016; 167(1):192–203. https://doi.org/10.1016/j.trsl.2015.08.004
68. Choy D.F., Hart K.M., Borthwick L.A., Shikotra A., Nagarkar D.R., Siddiqui S., Jia G., Ohri C.M., Doran E., Vannella K.M. Th2 and Th17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med. 2015; 7(301):301ra129. https://doi.org/10.1126/scitranslmed.aab3142
69. Bhavani S., Tsai C.-L., Perusich S., Hesselbacher S., Coxson H., Pandit L., Corry D.B., Kheradmand F. Clinical and immunological factors in emphysema progression. Five-year prospective longitudinal exacerbation study of chronic obstructive pulmonary disease (LES-COPD). Am. J. Respir. Crit. Care Med. 2015; 192(10):1171–1178. https://doi.org/10.1164/rccm.201504-0736OC
70. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W., Wynn T.A. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 2010; 207(3):535–552. https://doi.org/10.1084/jem.20092121
Review
For citations:
Suprun S.V., Makeeva M.I. Some aspects of comorbidity between psoriasis and bronchopulmonary pathology (literature review). Bulletin Physiology and Pathology of Respiration. 2025;(98):163-174. (In Russ.) https://doi.org/10.36604/1998-5029-2025-98-163-174
Views:
8
Email this article 